Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
Key Highlights
- ➤KaiNETIC Phase 3 enrollment completed across three global trials evaluating ribupatide injection (KLRA)
- ➤Topline data from KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3 expected mid-2028
- ➤KaiNETIC-1 enrolled approximately 2,500 adults with obesity or overweight
- ➤KaiNETIC-2 enrolled approximately 1,200 adults with obesity and type 2 diabetes
- ➤KaiNETIC-3 compares ribupatide against placebo and semaglutide 2.4 mg
Expert Statements
Scott Wasserman, M.D., Chief Medical Officer of Kailera
“Obesity is a complex, chronic disease, and millions of people still struggle to find a treatment that meets their needs.”
Scott Wasserman, M.D., Chief Medical Officer of Kailera
“Completing enrollment across all three KaiNETIC trials is an important milestone that brings us one step closer to delivering ribupatide injection to patients as a potential best-in-class medicine.”
- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher
WALTHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the completion of enrollment in the KaiNETIC global Phase 3 clinical program. The KaiNETIC program, which encompasses three trials – KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3 – is evaluating ribupatide injection (also known as KAI-9531), an investigational once-weekly dual GLP-1/GIP receptor agonist peptide, for the treatment of people living with obesity or overweight.
Get started
Create a free account to read the full story.